Antengene Corporation, a Chinese clinical-stage therapeutics company focused on oncology, has secured a US$120 million in series B round of financing, jointly led by Boyu Capital and FountainVest, according to a statement released today.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?